Sfoglia per AUTORE
CABRAS MG
Collezione AOU Città della Salute di Torino

  

Items : 13

IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma. in Blood advances / Blood Adv. 2024 Mar 26;8(6):1541-1549. doi: 10.1182/bloodadvances.2023011251.

2024
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara
ASL Biella

Bonomini L; Vitolo U; Cesaretti M; Esposito F; Pirosa MC; Pinotti G; Dore F; Pisani F; Zanni M; Ghiggi C; Liberati AM; Annibali O; Cabras MG; Celli M; Orsucci L; Tani M; Bruna R; Vanazzi A; Tucci A; Merli F; Balzarotti M; Gaidano G; Sassone M; Zucca E; Botto B; Stathis A; Ferreri AJM; Chiappella A; Conconi A; et alii...

IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. in Haematologica / Haematologica. 2024 Aug 1;109(8):2564-2573. doi: 10.3324/haematol.2023.283918.

2024
AOU Alessandria
AOU Città della Salute di Torino

Bertoni F; Cavalli F; Landi F; Spina M; Re F; Pietrantuono G; Merli M; Houot R; Liberati AM; Haioun C; Devizzi L; Cartron G; Casasnovas RO; Angrilli F; Occhini U; Pulsoni A; Celli M; Califano C; Capochiani E; Cabras MG; Zanni M; Tilly H; Tessoulin B; Conconi A; Palombi F; Cavallo F; Morschhauser F; Gressin R; Marino D; et alii...

MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2021 Feb;8(2):e110-e121. doi: 10.1016/S2352-3026(20)30366-5.

2021
AOU Città della Salute di Torino
AOU Novara

Liberati AM; Novak U; Osborne W; Frezzato M; Fox CP; Davies A; Cascavilla N; Bernardi M; Gastaldi E; Cozens K; Bromberg JEC; Singh V; Fanni A; Re F; Patti C; McKay P; Olivieri J; Linton K; Nassi L; Cellini C; Botto B; Cattaneo C; Khwaja J; Luppi M; Calimeri T; Doorduijn JK; Re A; Cabras MG; Smith J; et alii...

A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):188. doi: 10.3390/cancers14010188.

2021
AOU Alessandria
AOU Città della Salute di Torino

Hermine O; Vitolo U; Guarini A; Fabbri A; Patti C; Latte G; Spina M; Pascarella A; Vallisa D; Merli F; Di Renzo N; Cabras MG; Moia R; Volpetti S; Tani M; Del Giudice I; Barbero D; Ghislieri M; Drandi D; Genuardi E; Evangelista A; Passera R; Hoster E; Ferrero S; Zaccaria GM; Kluin-Nelemans HC; Cortelazzo S; Dreyling M; Ladetto M; et alii...

CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL). in Frontiers in oncology / Front Oncol. 2021 Nov 5;11:730194. doi: 10.3389/fonc.2021.730194. eCollection 2021.

2021
AOU Città della Salute di Torino
AOU Novara

Chiappella A; Rusconi C; Ferreri AJM; Cabras MG; Annibali O; Gentile M; Olivieri A; Loseto G; Arcari A; Tisi MC; Nassi L; Di Rocco A; Gini G; Balzarotti M;

Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. in British journal of haematology / Br J Haematol. 2017 Aug;178(4):588-591. doi: 10.1111/bjh.14728. Epub 2017 May 9.

2017
AOU Città della Salute di Torino

Ceriani L; Martelli M; Conconi A; Zinzani PL; Ferreri AJM; Botto B; Stelitano C; Gotti M; Cabras MG; Rigacci L; Giovanella L; Zucca E; Johnson PWM; Ceriani L; Martelli M; Conconi A; Zinzani PL; Ferreri AJM; Botto B; Stelitano C; Gotti M; Cabras MG; Rigacci L; Giovanella L; Zucca E; Johnson PWM;

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. in The Lancet. Oncology / Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.

2017
AOU Città della Salute di Torino

Tucci A; Cabras MG; Congiu AG; Gotti M; Castellino A; Russo E; Cascavilla N; D'Arco A; Zaja F; Rigacci L; Pavone V; Gaidano G; Merli F; Balzarotti M; Rossi G; Stelitano C; Carella AM; Evangelista A; Brusamolino E; Angelucci E; Martelli M; Chiappella A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U;

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. in Blood / Blood. 2017 Apr 20;129(16):2328-2330. doi: 10.1182/blood-2017-01-764258. Epub 2017 Mar 6.

2017
AOU Città della Salute di Torino

Zinzani PL; Pellegrini C; Chiappella A; Di Rocco A; Salvi F; Cabras MG; Argnani L; Stefoni V;

Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers. in Cancer medicine / Cancer Med. 2016 Oct;5(10):2740-2755. doi: 10.1002/cam4.865. Epub 2016 Sep 26.

2016
AOU Città della Salute di Torino
AOU Novara

Paulli M; Santucci M; Zinzani PL; Pimpinelli N; Rupoli S; Gambacorta M; Ascani S; Fierro MT; Onida F; Fraternali-Orcioni G; Zerbinati N; Cabras MG; Franceschetti S; Rattotti S; Alaibac M; Ramponi A; Grandi V; Dallera E; Arra M; Riboni R; Quaglino P; Tomasini C; Goteri G; Klersy C; Maffi A; Croci GA; Arcaini L; Berti E; Lucioni M; et alii...

Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results. in Blood cancer journal / Blood Cancer J. 2016 May 13;6(5):e425. doi: 10.1038/bcj.2016.29.

2016
AOU Città della Salute di Torino

Stefoni V; Casadei B; Bottelli C; Gaidano G; Ciochetto C; Cabras MG; Ansuinelli M; Argnani L; Broccoli A; Gandolfi L; Pellegrini C; Zinzani PL;

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. in Leukemia & lymphoma / Leuk Lymphoma. 2016 Aug;57(8):1823-30. doi: 10.3109/10428194.2015.1106536. Epub 2015 Dec 15.

2016
ASL Vercelli
AOU Città della Salute di Torino

Cox MC; Gentile M; Marino D; Ghio F; Savini P; Carli G; Musto P; Ilariucci F; Zambello R; Santagostino A; Cabras MG; Tani M; Marasca R; Valenti V; Bernuzzi P; Zanlari L; Spina M; Chiappella A; Arcari A; Vallisa D;

PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL). in Thrombosis research / Thromb Res. 2016 Apr;140 Suppl 1:S177. doi: 10.1016/S0049-3848(16)30136-0. Epub 2016 Apr 8.

2016
AOU Città della Salute di Torino

Santi RM; Ceccarelli M; Catania G; Monagheddu C; Evangelista A; Bernocco E; Monaco F; Federico M; Vitolo U; Cortelazzo S; Cabras MG; Spina M; Baldini L; Boccomini C; Chiappella A; Bari A; Luminari S; Calabrese M; Levis A; Visco C; Contino L; Ciccone G; Ladetto M;

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. in Blood / Blood. 2015 Aug 20;126(8):950-6. doi: 10.1182/blood-2014-12-616474. Epub 2015 Jun 18.

2015
AOU Città della Salute di Torino

Ceriani L; Martelli M; Zinzani PL; Ferreri AJ; Botto B; Stelitano C; Gotti M; Cabras MG; Rigacci L; Gargantini L; Merli F; Pinotti G; Mannina D; Luminari S; Stathis A; Russo E; Cavalli F; Giovanella L; Johnson PW; Zucca E;